Chronic Kidney Disease Trial, Recruiting NCT06752577 Sponsor: Mayo Clinic Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT06752577
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are over 18 years of age
  • People whose kidneys are working at a reduced level (a kidney function score below 60 mL/min/1.73m²)
  • People with diabetes whose blood sugar control meets a specific threshold (a blood test called HbA1c showing 9% or below)
  • People who have received a kidney transplant, provided their kidney function is reduced and has been getting worse over at least 6 months
  • People who are able to understand and agree to take part in the study on their own behalf

Who may not be able to join:

  • People with severe anaemia (low red blood cell levels below a certain point)
  • People who weigh more than 150 kg or have a BMI above 50
  • People with high blood pressure that remains very elevated even when taking maximum doses of at least two different types of blood pressure medication
  • People with a history of persistently very low blood pressure
  • People whose kidneys have already failed and who are currently on dialysis (either haemodialysis or peritoneal dialysis)
  • People currently taking high-dose immune-suppressing medications long-term (for example, prednisone at 20 mg or more daily)
  • People who have had a transplant of a solid organ other than a kidney (for example, a heart or liver transplant)
  • Kidney transplant recipients who are currently being treated for an active rejection episode
  • People who have been hospitalised in the past 3 months for a heart attack, stroke, or severe heart failure, or who have uncontrolled heart rhythm problems
  • People with a history of liver cirrhosis (severe liver scarring)
  • People with chronic lung conditions such as COPD or asthma that require daily medication
  • People with a history of recurring blood clots (such as deep vein thrombosis or pulmonary embolism) who need ongoing blood-thinning medication
  • People who are currently pregnant
  • People who are sexually active and able to become pregnant or father a child, and who are unwilling to use contraception for at least 2 months after receiving the study treatment
  • People with an active cancer
  • People with an active infection (including specific infections relevant to kidney transplant recipients — confirm with trial site)
  • People who have had a COVID-19 infection within the past month
  • People with a history of hepatitis B or C that has not been cured, or HIV infection
  • People who have previously had an allergic reaction to cellular products such as blood transfusions or platelets
  • People who currently use tobacco
  • People who currently use illicit drugs or drink alcohol excessively
  • People with significant psychosocial circumstances that may make it difficult to complete all study visits and procedures (confirm with trial site)
  • People who expect to travel for extended periods or face other circumstances that would prevent them from attending scheduled study visits
  • People who are unable to give informed consent

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: LaTonya J Hickson, MD, Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida

Phone: 507-255-7975

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
22 December 2024
Est. completion
31 December 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Adverse events and/or serious adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov